Alchornea cordifolia is used traditionally for the treatment of infertility and venereal diseases. Thirty rats were randomly divided into five groups of six rats each: Group 1 (distilled water), group 2 (7 mg/kg sodium arsenite), group 3 (7 mg/kg sodium arsenite and 100 µg/kg polyphenol-rich fraction 1 of A. cordifolia), group 4 (7 mg/kg sodium arsenite + 100 µg/kg polyphenol-rich fraction 2) and group 5 (7 mg/kg sodium arsenite + α-tocopherol). The experiment lasted 30 consecutive days. Biochemical markers of oxidative stress and antioxidants, male reproductive hormones, spermatozoa function tests, histopathology, immunoreactivity of androgen receptor binding protein (ARBP) and anti-apoptotic B-cell lymphoma-2 protein expressions were estimated. Data were analysed using descriptive statistics and ANOVA at p < .05. Treatment with AF1 significantly decreased markers of oxidative stress, but increased the systemic antioxidants, testosterone, FSH, spermatozoa count and motility. Histopathological lesions of necrosis and germinal epithelial sloughing observed in sodium arsenite group were absent in sodium arsenite + 100 µg/kg polyphenol-rich fraction 1 group. Expressions of androgen receptor binding protein and anti-apoptotic B-cell lymphoma-2 were highest in sodium arsenite + 100 µg/kg polyphenol-rich fraction 1 group. In conclusion, the polyphenol-rich fraction of A. cordifolia is protective against sodium arsenite-induced infertility in male rats through the inhibition of oxidative and apoptotic mechanisms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/and.13754 | DOI Listing |
Biomacromolecules
June 2021
Laboratoire de Chimie de Coordination du CNRS, 205 Route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France.
The long-term treatment of tuberculosis (TB) sometimes leads to nonadherence to treatment, resulting in multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. Inadequate bioavailability of the drug is the main factor for therapeutic failure, which leads to the development of drug-resistant cases. Therefore, there is an urgent need to design and develop novel antimycobacterial agents minimizing the period of treatment and reducing the propagation of resistance at the same time.
View Article and Find Full Text PDFCochrane Database Syst Rev
June 2004
Department of Paediatric Gastroenterology, Central Manchester and Manchester Children's University Hospitals, Booth Hall Children's Hospital, Charlestown Road, Blackley, Manchester, UK, M9 7AA.
Background: Crohn's disease may be refractory to conventional treatments such as corticosteroids, enteral nutrition and immuno-suppressive agents. A number of patients with the disease may also become steroid-dependent leading to increased risk of developing steroid-related adverse effects. Recent studies suggest that TNF-a blocking agents may be effective in inducing remission in Crohn's disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!